The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review

Skin Cancer

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Eur J Cancer.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C

doi: 10.1016/j.ejca.2017.05.038.

Endocrine and Neuroendocrine Tumors (NET)Skin Cancer

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

healthbook TIMES Oncology Hematology

Zihlera D, Vollmera K, Cozzio A

doi: 10.36000/hbT.OH.2019.01.003

SPECIAL REPORT

Genitourinary CancerLung, Respiratory and Thoracic CancerSkin Cancer

Meet the Expert

doi: 10.1056/NEJMoa1504627 (2015).

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade

J Immunother Cancer.

Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, Zippelius A, Stenner-Liewen F

doi: 10.1186/s40425-017-0249-y.

RECOMMENDED

Skin Cancer

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

J Immunother.

Dimitriou F, Matter AV, Mangana J, Urosevic-Maiwald M, Micaletto S, Braun RP, French LE, Dummer R

doi: 10.1097/CJI.

Skin Cancer

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

J Hematol Oncol.

Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A

doi: 10.1186/s13045-016-0309-7.

Skin Cancer

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

Cancer Immunol Immunother.

Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, Mozzillo N

doi: 10.1007/s00262-016-1898-2.

Gynecologic Cancer

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report

Gynecol Oncol Res Pract.

Paraghamian SE, Longoria TC, Eskander RN

doi: 10.1186/s40661-017-0038-9.

Gastrointestinal Cancer

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line

Case Rep Oncol.

Akhoundova Sanoyan D, Reiner CS, Papageorgiou P, Siebenhüner AR

doi: 10.1159/000504471.

Related content

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

Meet the Expert

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line